Results of the noninferiority analysis.
| Efficacy Criteria | Comparator | Probability of Noninferiority | |
|---|---|---|---|
| Random-effects Model | Fixed-effects Model | ||
| ACR20 | Mean of all treatments | 0.999 | 1.0 |
| Infliximab | 1.0 | 1.0 | |
| Etanercept | 0.901 | 0.951 | |
| Adalimumab | 0.998 | 1.0 | |
| Golimumab | 0.996 | 1.0 | |
| Anakinra | 0.998 | 1.0 | |
| Tocilizumab | 0.998 | 1.0 | |
| ACR50 | Mean of all treatments | 0.929 | 0.989 |
| Infliximab | 0.992 | 1.0 | |
| Etanercept | 0.634 | 0.682 | |
| Adalimumab | 0.948 | 0.998 | |
| Golimumab | 0.925 | 0.989 | |
| Anakinra | 0.991 | 1.0 | |
| Tocilizumab | 0.950 | 0.990 | |
| ACR70 | Mean of all treatments | 0.539 | 0.501 |
| Infliximab | 0.995 | 1.0 | |
| Etanercept | * | * | |
| Adalimumab | 0.956 | 0.987 | |
| Golimumab | * | * | |
| Tocilizumab | 0.891 | 0.917 | |
↵* Insufficient numbers of patients.